Tag:

UCB Pharma

Latest Headlines

Latest Headlines

Belgium's UCB calls it quits on $1.53B sale of U.S. generic drug unit

Weeks after Belgium's UCB announced that it would sell its U.S. generic drug business for $1.53 billion, the company is calling off the sale in light of regulatory pushback over one of the unit's products.

UCB joins pharma's slimdown craze, unloads U.S. generic drug business for $1.53B

Amid the pharma's slimdown craze, Belgium's UCB is getting in on the action by selling its U.S. generic drug unit for $1.53 billion.

With inversion pushback mounting, Akorn eyes bid for UCB subsidiary

The threat of action from lawmakers may have put a damper on pharma's tax inversion frenzy, but it has not stopped the wave of deals that are taking American drugmakers overseas. Next up could be Illinois' Akorn, which is reportedly looking into a bid for Belgian pharma UCB's U.S. subsidiary.

UCB hops on pharma's spinoff wagon with potential $2B sale of generics business

Shedding noncore assets is the trend du jour in Big Pharma, and now another company may be jumping on the bandwagon. Belgium's UCB is reportedly looking into a sale of Kremers Urban Pharmaceuticals, its Princeton, NJ-based generics unit.

UCB taps biopharma chief to step up to CEO job, prep for new launches

UCB is preparing for a changing of the guard. The Belgium-based drugmaker has tapped Jean-Christophe Tellier, who heads up its biopharma brands unit, to take over as CEO beginning next year, replacing current chief Roch Doliveux.

UCB sells off Rochester plant; buyer to keep 300 workers

he sale to France-based Unither includes a 6-year supply deal, and the buyer plans to keep UCB's 250 employees and 50 contract workers.

Lyrica matches UCB drug in Pfizer's latest epilepsy trial

Pfizer's attempts to prove Lyrica effective as an epilepsy treatment have delivered mixed results. Just three months ago, the controlled-release formula failed a Phase III trial in adults with epilepsy. But now, the company has unveiled new data showing that Lyrica capsules matched the UCB seizure drug Keppra at reducing a common type of seizures in epilepsy patients.

Shire, UCB see new-drug growth as Allergan, Hospira fall short

There's a bumper crop of numbers today as pharma's earnings season winds down. The dominant trends continue--the stronger dollar, generic competition (for branded drugmakers), new copycat products (for generics firms) and lots of expectations-management.

Nodality, UCB Pharma ink multiyear companion diagnostics deal

South San Francisco personalized medicine/diagnostics startup Nodality has signed a multi-year collaborative deal with Belgium's UCB Pharma that will initially focus on possible companion diagnostics

UCB to pay $34M for off-label marketing

Yet another drugmaker has joined the off-label marketing club. UCB agreed to pay $34 million to resolve claims it marketed its epilepsy drug Keppra to treat headaches and pain, uses not approved by